Title: Accelerating Autoimmune Drug Discovery: Humanized Mouse Models for Atopic Dermatitis and Asthma
Description:
Th2-driven inflammatory diseases such as atopic dermatitis (AD) and asthma continue to present significant unmet medical needs, where species differences often limit the translational relevance of conventional animal models. As drug development expands beyond monoclonal antibodies to advanced modalities such as bispecific antibodies and antibody–drug conjugates (ADCs), there is a growing need for reliable in vivo models capable of accurately evaluating human-specific therapeutic targets.
In this webinar, we will introduce Biocytogen’s portfolio of target-humanized mouse models for asthma and AD, featuring clinically validated targets such as IL-4Rα, TSLP, OX40, IL-33 and IL-13. By replacing endogenous murine genes with their human counterparts, these models enable direct in vivo efficacy and safety evaluation of human biologics—eliminating the need for surrogate antibodies, supporting mechanism-driven study design, and accelerating decision-making for next-generation immunology therapeutics across multiple modalities.
Key Highlights:
